Tigilanol tiglate

Tigilanol tiglate is a pharmaceutical drug used in the treatment of canine mast cell tumors. It is a small molecule isolated from the seed of the Australian blushwood tree (Hylandia dockrillii).

History[edit | edit source]

Tigilanol tiglate was developed by QBiotics, a life sciences company. The drug was approved by the European Medicines Agency (EMA) in 2020 for the treatment of non-resectable mast cell tumors in dogs.

Mechanism of Action[edit | edit source]

Tigilanol tiglate works by activating Protein Kinase C (PKC), which leads to a series of events causing tumor cells to die and the body to reject the tumor. The drug is injected directly into the tumor, causing it to become necrotic and eventually slough off.

Side Effects[edit | edit source]

Common side effects of tigilanol tiglate include pain or discomfort at the injection site, vomiting, and diarrhea. More serious side effects can include severe skin reactions and systemic allergic reactions.

Veterinary Use[edit | edit source]

Tigilanol tiglate is used in veterinary medicine for the treatment of mast cell tumors in dogs. It is particularly useful for tumors that cannot be surgically removed.

Human Use[edit | edit source]

While tigilanol tiglate is currently only approved for use in dogs, research is ongoing into its potential use in humans. Early studies suggest it may be effective in treating certain types of skin cancer.

See Also[edit | edit source]

Tigilanol tiglate Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.